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Background: Experimental data suggests that exclusive heart rate reduction with ivabradine is associated with the
amelioration of the endothelial function. Since it is presently unknown whether this also applies to humans, the
aim of this pilot study was to investigate whether heart rate reduction with ivabradine modulates the endothelial
function in humans with an established coronary heart disease.
Methods: Using high-sensitivity ultrasound, we analysed the flow-mediated (FMD) and nitro-mediated dilation
(NMD) of the brachial artery in 25 patients (62.9 ± 8.4 years) with a stable coronary heart disease and a resting heart
rate of ≥70 beats per minute (bpm). To assess acute effects, measurements were performed before and 4 hours
after the first intake of ivabradine 7.5 mg. Sustained effects of an ivabradine therapy (5 mg to 7.5 mg twice daily)
were investigated after 4 weeks.
Results: We found a significant decrease in heart rate, both 4 hours after the intake of 7.5 mg of ivabradine
(median −8 [interquartile range (IQR) -14 to −4] bpm) and after 4 weeks of twice daily intake (median −10 [IQR-17
to −5] bpm) (p < 0.05). However, the FMD did not change significantly: neither after first dose of ivabradine nor after
sustained therapy (baseline FMD: median 5.0 [IQR 2.4 to 7.9]%; FMD 4 hours after 7.5 mg of ivabradine: median 4.9
[IQR 2.7 to 9.8]%; FMD after 4 weeks of ivabradine therapy: median 6.1 [IQR 4.3 to 8.2]%). No significant changes of
the NMD were observed. In regression analysis, the heart rate and FMD did not correlated, irrespective of the
ivabradine intake (r2 = 0.086).
Conclusion: In conclusion, in our study heart rate reduction through ivabradine does not improve the endothelial
function in patients with a stable coronary heart disease. Moreover, we found no correlation between the heart rate
and the endothelial function.
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Figure 1 Flow-chart of the study protocol. HR: heart rate; Iva: ivabradine; FMD: flow-mediated dilation; NMD: nitro-mediated dilation.
Table 1 Baseline characteristics
Mean ± SD
Age (years) 62.9 ± 8.4
BMI (kg/m2) 27.7 ± 4.9
Heart rate (bpm) 82.4 ± 10.8
RR syst. (mmHg) 126.7 ± 16.2
RR diast. (mmHg) 76.8 ± 9.0
LVEF (%) 54.8 ± 8.6
Glucose (mg/dl) 109.5 ± 34.3
Cholesterol (mg/dl) 177.8 ± 50.7
LDL (mg/dl) 106.0 ± 40.1
HDL (mg/dl) 56.4 ± 25.9
Triglycerides (mg/dl) 132.2 ± 54.9
BMI = body mass index; RR syst. = systolic blood pressure; RR diast. = diastolic
blood pressure; LVEF = left ventricular ejection fraction; LDL = low-density
lipoprotein; HDL = high-density lipoprotein.
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Numerous epidemiologic studies suggest that an ele-
vated heart rate (HR) is associated with an increase in
cardiovascular morbidity and mortality [1-5]. This nega-
tive prognostic value of a higher HR appears to be inde-
pendent of traditional cardiovascular risk factors [1,6,7].
In addition, experimental and clinical evidence indicates
that an increased HR contributes to the pathogenesis of
atherosclerosis. Oxidative stress, expanded levels of low
shear-stress periods and increased mechanical burden
are discussed as underlying mechanisms [8-10]. There
are some clues that the HR modulates the endothelial
function as well; however, results are controversial. Both
positive as well as negative correlations of the HR with
the FMD as parameter of endothelial-dependent vaso-
dilation have been described [11-14].
Ivabradine (Iva), a selective inhibitor of If channels, re-
duces the resting and exercise HR without affecting car-
diac contractility, blood pressure, intracardiac conduction,
or ventricular repolarisation [15-17]. It therefore offers the
unique opportunity to assess effects of an exclusive HR
reduction [5]. Since it is presently unknown whether
changes in the HR have an impact on the endothelial
function in humans, the aim of our study was to investi-
gate effects of a HR reduction in response to Iva on the




Patients with a stable coronary heart disease and beta-
blocker intolerance (chronic obstructive lung disease,
asthma, psoriasis, hypotension, Raynaud’s syndrome) or
with an insufficient HR reduction during betablocker
treatment were included in the study from January 2010
to September 2011. The main inclusion criterion was a
resting HR of ≥70 beats/min in two consecutive ECGs.
Exclusion criteria were a recent (<2 months) myocardial
infarction or revascularisation procedures (<4 weeks),
ventricular or atrioventricular pacing, atrial fibrillationor flutter. We required routine laboratory parameters to
lay within the normal range. It was also necessary that
blood lipids, blood pressure, body mass index (BMI) and
HbA1c as well as glucose levels demonstrated good ad-
justment according to guidelines for secondary prevention
in coronary heart disease [18]. The study was approved by
the Charité University Hospital Ethics Committee (CEC),
and participants provided their written informed consent.
The study was carried out in accordance with the Code of
Ethics of the World Medical Association (Declaration of
Helsinki).
Study design
This prospective, non-randomized study was designed to
evaluate the acute and sustained effects of Iva on the
endothelial function. At the first study visit (control),
baseline FMD/NMD data were assessed in the morning
after a 12-hour overnight fast and 4 hours thereafter. At
the second study visit, FMD/NMD measurements were
performed before and 4 hours after a first dose of Iva
(7.5 mg) to investigate acute effects on the endothelial
function. After the morning measurement, patients







Myocardial infarction 10 (40)
CABG/PCI 20 (80)
ICD 2 (8)
Angina pectoris 17 (68)
β-blocker 11 (44)
CABG = coronary artery bypass graft; PCI = percutaneous coronary intervention;
ICD = implantable cardiac defibrillator.
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wheat rolls, one package of low fat cream cheese (1,5% fat
per 100 g) and half a liter of still water. Patients thereafter
received Iva (5 mg) twice daily for four weeks. In case of a
HR of ≥60/min at day 14 (documented in two resting
ECGs at least 5 min apart), the Iva dosage was increased
to 7.5 mg twice daily. After 4 weeks of Iva intake, FMD/
NMD values were assessed again at 08.00 a.m. (sustained
effect). Blood pressure and HR were documented simul-
taneously at each time point (Figure 1).
Flow-mediated dilation (FMD) and nitro-mediated dilation
(NMD)
The endothelial function was measured by high-resolution
vascular ultrasound with a 13-MHz linear-array trans-
ducer (Sonoline Antares, Siemens, Germany), as recently
described [19]. The endothelium-dependent FMD was
assessed by measuring the change in the brachial artery
diameter during reactive hyperaemia after cuff occlusion
of the forearm for 5 min, according to established guide-
lines [20,21]. To improve the accuracy and reproducibi-
lity of the measurements, an attached device fixed theTable 3 Median values of FMD and NMD
Baseline
8.00 a.m. 12.00 a.m.
FMDbase (mm) 3.8 [3.3-4.2] 3.8 [3.4-4.2]
FMDmax(mm) 3.9 [3.5-4.3] 4.0 [3.6-4.3]
FMDmax (%) 4.8 [2.4-6.5] 5.3 [2.2-7.5]
NMDbase (mm) 3.6 [3.2-4.2] 4.1 [3.4-4.2]
NMDmax (mm) 4.4 [4.1-4.8] 4.4 [4.2-4.9]
NMDmax (%) 19.1 [13.2-25.7] 17.0 [12.5-23.7]
Values are presented as median values (Q1 – Q3). FMDbase: diameter of brachial art
after hyperaemic stimulus, shown in mm as maximum percentage change in brach
artery before application of 0.4 mg nitroglycerine; NMDmax: maximum dilation of br
maximum percentage change in brachial artery diameter compared with FMDbase..
effect: FMD before and 4 hours after first intake of 7,5 mg ivabradine; Sustained effultrasound probe at one site of the brachial artery during
the entire period of measurements. Changes in the arterial
diameter were measured every 15 sec up to 3 min. The
FMD was defined as the maximum percentage change in
diameter compared with the baseline measurement. The
nature of the stimulus and conditions of the mea-
surements of FMD were chosen to obtain a nitric oxide-
dependent response after a brief period of shear stress in
the brachial artery [21]. The endothelium-independent
vasodilation (NMD) was determined after sublingual ap-
plication of nitroglycerin spray (0.4 mg). The increase in
diameter of the brachial artery was measured from min 1
to 6, and the NMD was defined as the maximum percen-
tage change in diameter compared with the baseline
measurement. Ultrasound images were digitized online
and saved. Analyses of diameter changes were conducted
offline (Tom Tec Imaging Systems, Germany) by an inves-
tigator blinded to subject treatment. Intra- and interob-
server variations for FMD max (%) were 0.97 and 0.91
and for NMD max (%) 0.99 and 0.98 in 20 by random
chosen studies.
Statistical analysis
Values for the FMD and HRs in tables, text and figures
are presented as median values (Q1 – Q3). The baseline
characteristics are means ± standard deviation. All statis-
tical tests were two-sided with the level of significance at
5%. The non-parametric test design was chosen because
of the small sample size. The paired design was consi-
dered by using the Wilcoxon test. Comparison between
the FMD and HR took place with regression analysis.
Statistical analyses were performed by using IBM SPSS
Statistics Version 20.
Results
A total of 25 patients were included in the study arm to
investigate the acute effects of Iva on the endothelial
function. In 17 of these patients, the sustained effects of
an up to four weeks long Iva therapy were assessed.Acute effect Sustained effect
8.00 a.m. 12.00 a.m. 8.00 a.m.
3.7 [3.3-4.2] 3.6 [3.3-4.1] 3.6 [3.4-4.3]
3.8 [3.5-4.3] 3.9 [3.5-4.3] 3.8 [3.6-4.4]
5.0 [2.4-7.9] 4.9 [2.7-9.8] 6.1 [4.3-8.2]
3.8 [3.1-4.4] 4.1 [3.3-4.4] 3.7 [3.3-4.2]
4.4 [3.9-5.0] 4.4 [4.1-5.1] 4.4 [4.1-4.9]
16.7 [13.0-24.6] 17.3 [9.8-23.7] 21.1 [13.5-29.6]
ery before hyperaemic stimulus; FMDmax : maximum dilation of brachial artery
ial artery diameter compared with FMDbase; NMDbase: diameter of brachial
achial artery after application of 0.4 mg nitroglycerine, shown in mm and as
Baseline: FMD at 08.00 and 12.00 at study visit 1 (without ivabradine); Acute





















Figure 3 FMD during study protocol. Values are presented as
median (Q1-Q3). Iva: ivabradine; FMD: flow-mediated dilation; baseline:
difference between FMD at 08.00 and 12.00 at study visit 1 (without Iva);
Iva acute effect: difference between FMD before and 4 hours after Iva;
Iva sustained effect: difference between FMD before first dose of Iva
(study visit 2) and after 4 weeks of Iva intake twice daily (10 to 15 mg).
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are depicted in Tables 1 and 2. The mean age was
62.9 ± 8.4 years and the mean BMI 27.7 ± 4.9 kg/m2. 44%
of patients were receiving betablocker treatment. Me-
dians of FMD and NMD measurements over the whole
study period are shown in Table 3. We found a signifi-
cant decrease in the HR both 4 hours after the intake of
7.5 mg of Iva (−8 [−14 to −4] bpm) and after 4 weeks of
twice daily intake (−10 [−17 to −5] bpm), shown in
Figure 2. However, the FMD did not change signifi-
cantly: neither after the first dose of Iva nor after sus-
tained therapy (baseline FMD: 5.0 [2.4 to 7.9]%; FMD
4 hours after 7.5 mg of Iva: 4.9 [2.7 to 9.8]%; FMD after
4 weeks of Iva therapy: 6.1 [4.3 to 8.2]%) (Figure 3). Iva
failed to modulate the endothelial function regardless of
the presence or absence of concomitant betablocker
therapy (data not shown). Moreover, the degree of HR
reduction had no influence on Iva effects (data not
shown). No significant changes of NMD were observed.
Median values for FMD and NMD measurements are
depicted in Table 3. In regression analysis, HR and FMD
did not correlate, irrespective of Iva intake (r2 = 0.086)
(Figure 4).
Discussion
The main finding of our study is that Iva treatment is not
associated with a significant amelioration of the endothe-
lial function in patients with stable coronary artery dis-























Figure 2 Heart rate during study protocol. Values are presented
as median (Q1-Q3)..Iva: ivabradine; baseline: difference between
heart rate at 08.00 and 12.00 at study visit 1 (without Iva); Iva acute
effect: difference between heart rate before and 4 hours after Iva;
Iva sustained effect: difference between heart rate before first dose
of Iva (study visit 2) and after 4 weeks of Iva intake twice daily
(10 to 15 mg). *p < 0.05 for Iva acute effects vs. baseline and Iva
sustained effects vs. baseline.the endothelial-dependent vasodilation assessed non-inva-
sively by high-sensitivity ultrasound of the brachial artery
were observed: neither acutely nor after one month of
treatment with Iva. Even in the patient subgroup with the
highest HR at baseline and with the greatest reduction in
response to Iva, we found no significant impact on the
endothelial function.
These results are in line with two recently published
trial in humans which also did not find an improvement
of the FMD after Iva treatment of diabetic patients and of
patients with angina pectoris despite a profound reduction
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Figure 4 Heart rate and FMD. Regression analyses of heart rate and
FMD irrespective of ivabradine intake. FMD: flow-mediated dilation.
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several occasions in mice with lipid-induced endothelial
dysfunction, which reveals that endothelial-dependent vaso-
dilation improves in response to a HR reduction with this
If-channel blocker [8-10,24]. Drouin reported in 2008 that
Iva prevents deterioration of the endothelial dilator func-
tion of renal and cerebral arteries associated with dyslipi-
demia in mice expressing human ApoB-100 [9]. Similarly,
in apolipoprotein E-deficient mice fed a Western-type
diet, Iva improved the endothelial function in aortic rings,
exerted potent antioxidative effects and reduced athero-
sclerotic plaque formation [8]. These effects were inde-
pendent of blood pressure or lipid lowering [8]. Very
recently, Schirmer et al. showed that Iva enhanced arterio-
genesis and increased eNOS expression, NO availability
and endothelial-dependent relaxation in a murine hind-
limb model of endothelial dysfunction [24]. HR reduction
has been incriminated as the main underlying mode of ac-
tion, since Iva had no direct effect on the endothelium:
neither in cultured endothelial cells nor in isolated rings
from ApoE−/− mice [24].
The reasons for the inconsistent results between our
data in humans and in animal models are unclear; how-
ever, species differences may be of importance. The HR
is usually below 100 beats/min in humans and above
600 beats/min in small animals such as mice. Harzheim
et al. reported that HCN4 channels serve to regulate the
HR in adult mice only during and after stress and that,
accordingly, effects of Iva may not be directly compared
to data obtained in humans [25,26].
Principally, the paradigm must be questioned that
there is a comprehensive correlation between the level
of the HR and the endothelial function. As mentioned
before, human studies assessing this correlation have
yielded diverging results [11,13,14,26]. In a community-
based cohort of 2883 participants, a positive correlation
between the FMD and HR was found, which suggests
that an increased HR is associated with an improved
endothelial function [13]. In contrast, these two parame-
ters correlated inversely in smaller studies. In these in-
vestigations, a bias of the chosen triggers to modulate
the HR (e.g., physical activity or mental stress) cannot be
ruled out [11,14]. One study in pacemaker patients
found no effects of different cardiac pacing protocols
(80–120 bpm) on FMD [12]. To obtain further insights,
we analysed in our patient group whether the HR correlates
with FMD. The fact that this was not the case (Figure 4)
may explain why an HR reduction in response to Iva treat-
ment failed to modulate the endothelial function.
Limitations
Several limitations of our study must be considered. First,
because of the relatively small sample size, the study may
be not sufficiently powered to assess significant differences.Second, the absence of a placebo-controlled group may
have biased some results.
Third, the brachial diameter was not measured conti-
nuously as we didn’t use a semiautomatic system for
analyses of FMD and NMD. Nevertheless intra- and inter-
observer variations for FMD and NMD showed a good
accuracy of our methodology.
Conclusion
In conclusion, our data did not support the concept that a
reduction of the HR is beneficial with regard to the ame-
lioration of the endothelial function. There is no acute or
sustained effect on the flow-mediated dilation measured
by high-frequency ultrasound despite a significant HR
reduction.
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